ErbB3 is required for ductal morphogenesis in the mouse mammary gland

Breast Cancer Research

Volumn 10, Issue 6, 2008, Pages

  Jackson Fisher, Amy J ^a,b   Bellinger, Gary ^a,b   Breindel, Jerrica L ^a   Tavassoli, Fatteneh A ^a   Booth, Carmen J ^a   Duong, James K ^c   Stern, David F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BROXURIDINE; CADHERIN; CASP3 PROTEIN, MOUSE; CASPASE 3; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; EPITHELIUM; FEMALE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MORPHOGENESIS; MOUSE; MOUSE MUTANT; PHYSIOLOGY; SMOOTH MUSCLE; TRANSPLANTATION; UDDER;

ACTINS; ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CADHERINS; CASPASE 3; CELL PROLIFERATION; EPITHELIUM; FEMALE; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOGENESIS; MUSCLE, SMOOTH; RECEPTOR, ERBB-3;

EID: 63849238215     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2198     Document Type: Article

References (43)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516. 10.1038/nrm1962, 16829981.
2. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345. 10.1038/sj.onc.1210202, 17322919.
3. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16:1647-1655. 1169769, 9130710, 10.1093/emboj/16.7.1647.
4. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999, 96:4995-5000. 21805, 10220407, 10.1073/pnas.96.9.4995.
5. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996, 15:2452-2467. 450177, 8665853.
6. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287. 231527, 8816440.
7. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:215-223. 18454306, 10.1007/s10911-008-9083-7.
8. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 166416, 12853564, 10.1073/pnas.1537685100.
9. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765. 10.1002/ijc.11273, 12866037.
10. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001, 7:1957-1962.
11. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006, 6:46. 1431553, 16507107, 10.1186/1471-2407-6-46.
12. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004, 91:2034-2041. 10.1038/sj.bjc.6602251, 15583696.
13. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006, 24:4317-4323. 10.1200/JCO.2005.04.8397, 16896008.
14. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007, 97:453-457. 10.1038/sj.bjc.6603910, 17667926.
15. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441. 10.1038/nature05474, 17206155.
16. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007, 7:257-268. 10.1517/14712598.7.2.257, 17250463.
17. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007, 43:481-489. 10.1016/j.ejca.2006.11.007, 17208435.
18. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043. 10.1126/science.1141478, 17463250.
19. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007, 13:675-677. 10.1038/nm0607-675, 17554333.
20. Schroeder JA, Lee DC. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ 1998, 9:451-464.
21. Stern DF. ErbBs in mammary development. Exp Cell Res 2003, 284:89-98. 10.1016/S0014-4827(02)00103-9, 12648468.
22. Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, Derynck R, Hom YK, Cunha GR, DiAugustine RP. Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth Differ 1998, 9:777-785.
23. Jones FE, Jerry DJ, Guarino BC, Andrews GC, Stern DF. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth Differ 1996, 7:1031-1038.
24. Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA 2003, 100:8281-8286. 166220, 12824469, 10.1073/pnas.1436402100.
25. Erickson SL, O'Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, Lu LH, Moore MW. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997, 124:4999-5011.
26. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA 2004, 101:17138-17143. 535384, 15569931, 10.1073/pnas.0407057101.
27. Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 1999, 18:3481-3490. 10.1038/sj.onc.1202698, 10376526.
28. Li L, Cleary S, Mandarano MA, Long W, Birchmeier C, Jones FE. The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. Oncogene 2002, 21:4900-4907. 10.1038/sj.onc.1205634, 12118369.
29. Hinck L, Silberstein GB. Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res 2005, 7:245-251. 1410762, 16280048, 10.1186/bcr1331.
30. Silberstein GB. Postnatal mammary gland morphogenesis. Microsc Res Tech 2001, 52:155-162. 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P, 11169863.
31. Williams JM, Daniel CW. Mammary ductal elongation: differentiation of myoepithelium and basal lamina during branching morphogenesis. Dev Biol 1983, 97:274-290. 10.1016/0012-1606(83)90086-6, 6852366.
32. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, Krajewski S, Reed JC, Rosen JM. Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development 1996, 122:4013-4022.
33. Reginato MJ, Muthuswamy SK. Illuminating the center: mechanisms regulating lumen formation and maintenance in mammary morphogenesis. J Mammary Gland Biol Neoplasia 2006, 11:205-211. 10.1007/s10911-006-9030-4, 17115263.
34. Daniel CW, Strickland P, Friedmann Y. Expression and functional role of E- and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev Biol 1995, 169:511-519. 10.1006/dbio.1995.1165, 7781895.
35. Deugnier MA, Moiseyeva EP, Thiery JP, Glukhova M. Myoepithelial cell differentiation in the developing mammary gland: progressive acquisition of smooth muscle phenotype. Dev Dyn 1995, 204:107-117.
36. Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis 2006, 44:477-486. 10.1002/dvg.20243, 16991114.
37. Sternlicht MD, Kouros-Mehr H, Lu P, Werb Z. Hormonal and local control of mammary branching morphogenesis. Differentiation 2006, 74:365-381. 2580831, 16916375, 10.1111/j.1432-0436.2006.00105.x.
38. Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci 2002, 115:839-848.
39. Fata JE, Werb Z, Bissell MJ. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res 2004, 6:1-11. 314442, 14680479.
40. Wiseman BS, Sternlicht MD, Lund LR, Alexander CM, Mott J, Bissell MJ, Soloway P, Itohara S, Werb Z. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol 2003, 162:1123-1133. 2172848, 12975354, 10.1083/jcb.200302090.
41. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999, 126:335-344.
42. Kenney NJ, Smith GH, Rosenberg K, Cutler ML, Dickson RB. Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. Cell Growth Differ 1996, 7:1769-1781.
43. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126:2739-2750.